CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial Genotype-Guided Strategy for Oral P2Y12 Inhibitors Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association Development and validation of a simple risk score to predict 30-day readmission after percutaneous coronary intervention in a cohort of medicare patients Management of No-Reflow Phenomenon in the Catheterization Laboratory Association Between Living in Food Deserts and Cardiovascular Risk Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion: The DECISION-CTO Trial

Clinical Trial26 Sep 2019

JOURNAL:Circulation. Article Link

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial

S Windecker , RD Lopes, AUGUSTUS Investigators et al. Keywords: antithrombotic therapy; atrial fibrillation; ACS patients; safety and efficacy

FULL TEXT PDF